Danish pharmaceutical company Lundbeck has announced positive headline results from a new phase II clinical study with its Lu AA21004 compound for the treatment of depression. Lu AA21004 showed highly significant improvements on the primary efficacy endpoints compared to placebo, and had an attractive safety profile.
Anders Gersel Pedersen, head of development at Lundbeck says: "We are pleased that the encouraging results from this proof-of-concept study confirm our expectations of Lu AA21004 as a potent and well tolerated new drug for the treatment of depression".
Claus Bræstrup, group managing director of Lundbeck says: "The probability of Lu AA21004 reaching the market has multiplied. We will now bring the drug into phase III as quickly as possible, either this year or early next year. We have all the data needed, and it is especially encouraging that the data is razor-sharp, robust and unambiguous." "We see the potential for this drug to succeed Cipralex/Lexapro. I reckon the drug can be on the market in 2011."
Lu AA21004 is being jointly developed by Lundbeck and Takeda Pharmaceutical Company Limited. The news was reported by financial daily newspaper Børsen and in a press release from Lundbeck.
Lundbeck is an international pharmaceutical company engaged in R&D, production, marketing and sales of drugs for the treatment of psychiatric and neurological disorders. In 2006, the company generated revenues of DKK 9.2 billion (USD 1.67 bn). Lundbeck is headquartered in Copenhagen and employs approx 5,300 people globally. The news was reported by financial daily newspaper Børsen and in a Lundbeck press release.